Metabolism - Clinical and Experimental
Volume 59, Issue 6 , Pages 914-920, June 2010

Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor–γ agonist use in prediabetes

  • Kylie Kavanagh

      Affiliations

    • Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27127, USA
    • Corresponding Author InformationCorresponding author. Department of Pathology, Section on Comparative Medicine, Wake Forest University, Winston-Salem, NC 27127, USA. Tel.: +1 336 716 1555; fax: +1 336 716 1515.
  • ,
  • Kathleen K. Brown

      Affiliations

    • Glaxo Smith Kline, Research Triangle Park, NC, USA
  • ,
  • Mandy L. Berquist

      Affiliations

    • Glaxo Smith Kline, Research Triangle Park, NC, USA
  • ,
  • Li Zhang

      Affiliations

    • Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27127, USA
  • ,
  • Janice D. Wagner

      Affiliations

    • Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27127, USA

Received 15 July 2009; accepted 26 November 2009. published online 03 March 2010.

Abstract 

Pioglitazone is prescribed to improve insulin sensitivity in type 2 diabetes mellitus patients and has been discussed as a therapy for metabolic syndrome. Pioglitazone and other thiazolidinediones are associated with fluid retention and edema that may exacerbate existing or developing congestive heart failure, which is often present in these patients. Using a nonhuman primate model, our aims were to evaluate (1) whether fluid shifts were detectable in normoglycemic monkeys, (2) which fluid compartment changed, and (3) whether fluid retention was dose dependent. Seventeen adult male cynomolgus macaques (Macaca fascicularis) were studied in a Latin square design such that all animals received 0, 1, 2, and 5 mg/kg pioglitazone for 6 weeks with 2 weeks of washout between dosing intervals. Doses approximated human exposures achieved with 30, 45, and 60 mg. At the end of each period, animals were weighed and underwent dual-absorption x-ray absorption scanning for body composition measurements. Fluid volumes were quantitated by Evans blue dilution for plasma volume, equilibration of sodium bromide for extracellular water, and deuterated water for total body water. Significant (P < .05) effects were seen with expansion of PV at both the 2- and 5-mg/kg doses, along with reduced plasma sodium at 5 mg/kg; however, surrogate end points used to indicate fluid retention (body weight, hematocrit, total protein, and albumin) did not change significantly. Significant trends toward increases in interstitial fluid and extracellular water with increasing dose were apparent. Pioglitazone effectively improved metabolic status by significantly decreasing fasting glucose and triglycerides and increasing adiponectin. We conclude that thiazolidinedione-related plasma volume expansion occurs in nondiabetic primates and that fluid retention is detectable when compartments are directly measured.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0026-0495(10)00064-8

doi:10.1016/j.metabol.2010.02.010

Metabolism - Clinical and Experimental
Volume 59, Issue 6 , Pages 914-920, June 2010